EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Is Nuchal Translucency of 3.0–3.4 mm an Indication for cfDNA Testing or Microarray? – A Multicenter Retrospective Clinical Cohort Study

Magda Rybak-Krzyszkowska, Anna Madetko-Talowska, Katarzyna Szewczyk, Mirosław Bik-Multanowski, Agata Sakowicz, David Stejskal, Marie Trková, Dagmar Smetanová, Sílvia Serafim, Hildeberto Correia, Julian Nevado, Maria Angeles Mori und 7 weitere

Fetal Diagnosis and Therapy · 2024

DOI: 10.1159/000539463 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Fetal Diagnosis and Therapy, 2024. Verfasst von Magda Rybak-Krzyszkowska und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Perinatology University Hospital, Krakow, Poland. Hauptthemen laut MEDLINE: Nuchal Translucency Measurement. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to evaluate the occurrence of clinically relevant (sub)microscopic chromosomal aberrations in fetuses with the nuchal translucency (NT) range from 3.0 to 3.4 mm, which would be potentially missed by cfDNA testing.

Methods

A retrospective data analysis of 271 fetuses with NT between 3.0 and 3.4 mm and increased first trimester combined test (CT) risk in five cohorts of pregnant women referred for invasive testing and chromosomal microarray was performed.

Results

A chromosomal aberration was identified in 18.8% fetuses (1:5; 51/271). In 15% (41/271) of cases, trisomy 21, 18, or 13 were found. In 0.7% (2/271) of cases, sex chromosome aneuploidy was found. In 1.1% (3/271) of cases, CNV >10 Mb was detected, which would potentially also be detected by genome-wide cfDNA testing. The residual risk for missing a submicroscopic chromosome aberration in the presented cohorts is 1.8% (1:54; 5/271).

Conclusion

Our results indicate that a significant number of fetuses with increased CT risk and presenting NT of 3.0–3.4 mm carry a clinically relevant chromosomal abnormality other than common trisomy. Invasive testing should be offered, and counseling on NIPT should include the test limitations that may result in NIPT false-negative results in a substantial percentage of fetuses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nuchal Translucency MeasurementHumansFemaleRetrospective StudiesPregnancyAdultCell-Free Nucleic AcidsChromosome AberrationsChromosome DisordersMicroarray AnalysisCohort StudiesNoninvasive Prenatal Testing

Stichwörter der Autor:innen

Chromosomal microarrayIncreased nuchal translucencyNoninvasive prenatal testingPrenatal diagnosis

Substanzen

Cell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Obstetrics and Perinatology University Hospital, Krakow, Poland.
  • Hi-Gen Centrum Medyczne, Krakow, Poland.
  • Department of Medical Genetics, Institute of Paediatrics, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.
  • Department of Medical Biotechnology, Medical University of Lodz, Lodz, Poland.
  • Centre of Medical Genetics and Reproductive Medicine GENNET, Prague, Czechia.
  • Unidade de Citogenética, Departamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.

Zitieren

APA

Rybak-Krzyszkowska, M., Madetko-Talowska, A., Szewczyk, K., Bik-Multanowski, M., Sakowicz, A., Stejskal, D., Trková, M., Smetanová, D., Serafim, S., Correia, H., Nevado, J., Angeles Mori, M., Mansilla, E., Rutkowska, L., Kucińska, A., Gach, A., Huras, H., Kołak, M., & Srebniak, M. I. (2024). Is Nuchal Translucency of 3.0–3.4 mm an Indication for cfDNA Testing or Microarray? – A Multicenter Retrospective Clinical Cohort Study. Fetal Diagnosis and Therapy. https://doi.org/10.1159/000539463

Vancouver

Rybak-Krzyszkowska M, Madetko-Talowska A, Szewczyk K, Bik-Multanowski M, Sakowicz A, Stejskal D, et al. Is Nuchal Translucency of 3.0–3.4 mm an Indication for cfDNA Testing or Microarray? – A Multicenter Retrospective Clinical Cohort Study. Fetal Diagnosis and Therapy. 2024. doi:10.1159/000539463

BibTeX
@article{RybakKrzyszkowska2024,
  author = {Rybak-Krzyszkowska, Magda and Madetko-Talowska, Anna and Szewczyk, Katarzyna and Bik-Multanowski, Mirosław and Sakowicz, Agata and Stejskal, David and Trková, Marie and Smetanová, Dagmar and Serafim, Sílvia and Correia, Hildeberto and Nevado, Julian and Angeles Mori, Maria and Mansilla, Elena and Rutkowska, Lena and Kucińska, Agata and Gach, Agnieszka and Huras, Hubert and Kołak, Magdalena and Srebniak, Malgorzata Ilona},
  title = {Is Nuchal Translucency of 3.0–3.4 mm an Indication for cfDNA Testing or Microarray? – A Multicenter Retrospective Clinical Cohort Study},
  journal = {Fetal Diagnosis and Therapy},
  year = {2024},
  doi = {10.1159/000539463}
}
Kostenlos starten →